{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:09:59Z","timestamp":1761725399107,"version":"build-2065373602"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Department of Neurology, Ulm University","award":["Project Voice-HD"],"award-info":[{"award-number":["Project Voice-HD"]}]},{"name":"European Union \u2013 Next Generation EU: National institute for Neurological Research","award":["ID Project No. LX22NPO5107"],"award-info":[{"award-number":["ID Project No. LX22NPO5107"]}]},{"name":"Czech Ministry of Health","award":["grants nr. MH CZ- DRO-VFN64165","NW25-04-00052"],"award-info":[{"award-number":["grants nr. MH CZ- DRO-VFN64165","NW25-04-00052"]}]},{"DOI":"10.13039\/100007655","name":"Czech Technical University in Prague","doi-asserted-by":"crossref","award":["grant SGS \u201cBiological Signal Analysis","Modelling","Interpretation\u201d"],"award-info":[{"award-number":["grant SGS \u201cBiological Signal Analysis","Modelling","Interpretation\u201d"]}],"id":[{"id":"10.13039\/100007655","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Czech Ministry of Education","award":["Project Cooperation LF1","research area Neuroscience"],"award-info":[{"award-number":["Project Cooperation LF1","research area Neuroscience"]}]},{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In Huntington disease (HD), speech alterations are common and may emerge before onset of chorea. Slow and irregular motion rates, i.e. altered oral diadochokinesis (oDDK), are a distinctive feature. This study investigated oDDK using alternating (AMR) and sequential motion rate (SMR) tasks in manifest HD and explored the impact of antidopaminergic medications (ADM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Speech samples were acquired from 30 healthy controls (14 men; 27\u201378 years\u00b8 age- and gender-matched to HD subjects) and 35 individuals with early-to-moderate HD (18 men; 22\u201376 years) phenotyped using standardized scales (UHDRS\u201999) and MR imaging to estimate disease severity. Acoustic analysis was used to quantify rate and regularity of oDDK. In an exploratory subgroup analysis, the impact of ADMs on oDKK was explored by comparing patients with and without ADMs (HD-ADM: n\u2009=\u200916; 8 men; 22\u201376 years; HD-nADM; n\u2009=\u200919; 10 men; 28\u201361 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HD patients were slower and more irregular in AMR and SMR tasks (p\u2009&lt;\u20090.001) compared to controls. Analyses using area under the receiver-operating characteristic curve (AUC) showed the best characteristics for AMR (AUC\u2009=\u200995.0%). oDDK parameters correlated with measures of motor, cognitive and functional impairment and striatal atrophy. Patients on ADMs showed slower motion rates in both tasks (AMR p\u2009=\u20090.021; SMR p\u2009=\u00a00.026), but unchanged regularity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Decreased AMR performance alone captured early motor impairment accurately, reflects disease severity and is ADM-sensitive. Therefore, objective acoustic analysis of AMR performance is a simple measure which may serve as read-out to monitor disease progression, e.g. in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-025-13310-x","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:04:30Z","timestamp":1760540670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenging or less challenging oral diadochokinetic tasks\u2014what works best in Huntington disease? A cross-sectional study"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-8831","authenticated-orcid":false,"given":"Wiebke","family":"Hannemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8964-0955","authenticated-orcid":false,"given":"Lukas","family":"Stahuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-9886","authenticated-orcid":false,"given":"Tomas","family":"Kouba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8516-0577","authenticated-orcid":false,"given":"Katrin S.","family":"Lindenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0453-7318","authenticated-orcid":false,"given":"Daniel","family":"Rapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9272-529X","authenticated-orcid":false,"given":"Jan","family":"Lewerenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-9094","authenticated-orcid":false,"given":"Hans-J\u00fcrgen","family":"Huppertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1156-3709","authenticated-orcid":false,"given":"Tereza","family":"Tykalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-3054","authenticated-orcid":false,"given":"Jan","family":"Rusz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3375-790X","authenticated-orcid":false,"given":"G. Bernhard","family":"Landwehrmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-3071","authenticated-orcid":false,"given":"Alzbeta","family":"M\u00fchlb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"9557","key":"13310_CR1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO (2007) Huntington\u2019s disease. Lancet 369(9557):218\u2013228","journal-title":"Lancet"},{"issue":"6","key":"13310_CR2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"ME MacDonald","year":"1993","unstructured":"MacDonald ME et al (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72(6):971\u2013983","journal-title":"Cell"},{"key":"13310_CR3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/B978-0-444-52014-2.00004-5","volume":"100","author":"JP Vonsattel","year":"2011","unstructured":"Vonsattel JP, Keller C, Cortes Ramirez EP (2011) Huntington\u2019s disease - neuropathology. Handb Clin Neurol 100:83\u2013100","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"13310_CR4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ (1985) Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol 44(6):559\u2013577","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"13310_CR5","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1038\/s41598-020-61435-y","volume":"10","author":"JM Correia","year":"2020","unstructured":"Correia JM et al (2020) Phonatory and articulatory representations of speech production in cortical and subcortical fMRI responses. Sci Rep 10(1):4529","journal-title":"Sci Rep"},{"key":"13310_CR6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/B978-0-12-407794-2.00059-6","volume-title":"neurobiology of language","author":"P Tremblay","year":"2016","unstructured":"Tremblay P, Deschamps I, Gracco VL (2016) Chapter 59 - neurobiology of speech production: a motor control perspective. In: Hickok G, Small SL (eds) neurobiology of language. Academic Press, San Diego, pp 741\u2013750"},{"issue":"11","key":"13310_CR7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113412","volume":"9","author":"J Rusz","year":"2014","unstructured":"Rusz J et al (2014) Phonatory dysfunction as a preclinical symptom of Huntington disease. PLoS ONE 9(11):e113412","journal-title":"PLoS ONE"},{"issue":"14","key":"13310_CR8","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1016\/j.neuropsychologia.2012.09.011","volume":"50","author":"AP Vogel","year":"2012","unstructured":"Vogel AP et al (2012) Speech acoustic markers of early stage and prodromal Huntington\u2019s disease: a marker of disease onset? Neuropsychologia 50(14):3273\u20133278","journal-title":"Neuropsychologia"},{"issue":"5","key":"13310_CR9","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/ene.15726","volume":"30","author":"T Kouba","year":"2023","unstructured":"Kouba T et al (2023) Speech biomarkers in Huntington\u2019s disease: a cross-sectional study in pre-symptomatic, prodromal and early manifest stages. Eur J Neurol 30(5):1262\u20131271","journal-title":"Eur J Neurol"},{"key":"13310_CR10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.neubiorev.2019.08.009","volume":"107","author":"JCS Chan","year":"2019","unstructured":"Chan JCS, Stout JC, Vogel AP (2019) Speech in prodromal and symptomatic Huntington\u2019s disease as a model of measuring onset and progression in dominantly inherited neurodegenerative diseases. Neurosci Biobehav Rev 107:450\u2013460","journal-title":"Neurosci Biobehav Rev"},{"key":"13310_CR11","volume-title":"Motor speech disorders: substrates, differential diagnosis, and management","author":"J Duffy","year":"2019","unstructured":"Duffy J (2019) Motor speech disorders: substrates, differential diagnosis, and management, 4th edn. Elsevier, Maryland Heights","edition":"4"},{"key":"13310_CR12","doi-asserted-by":"crossref","unstructured":"HSG, Unified Huntington\u2019s disease rating scale: Reliability and consistency. Movement Disorders, 1996. 11: p. 136\u2013142.","DOI":"10.1002\/mds.870110204"},{"issue":"4","key":"13310_CR13","first-page":"649","volume":"33","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T et al (2013) Diadochokinetic movements differ between patients with Huntington\u2019s disease and controls. NeuroRehabilitation 33(4):649\u2013655","journal-title":"NeuroRehabilitation"},{"issue":"1","key":"13310_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000266338","volume":"47","author":"H Ackermann","year":"1995","unstructured":"Ackermann H, Hertrich I, Hehr T (1995) Oral diadochokinesis in neurological dysarthrias. Folia Phoniatr Logop 47(1):15\u201323","journal-title":"Folia Phoniatr Logop"},{"issue":"1","key":"13310_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1109\/TNSRE.2019.2943064","volume":"28","author":"K Rozenstoks","year":"2020","unstructured":"Rozenstoks K et al (2020) Automated assessment of oral diadochokinesis in multiple sclerosis using a neural network approach: effect of different syllable repetition paradigms. IEEE Trans Neural Syst Rehabil Eng 28(1):32\u201341","journal-title":"IEEE Trans Neural Syst Rehabil Eng"},{"issue":"2","key":"13310_CR16","first-page":"49","volume":"19","author":"LR Kaploun","year":"2011","unstructured":"Kaploun LR et al (2011) Acoustic analysis of voice and speech characteristics in presymptomatic gene carriers of Huntington\u2019s disease: biomarkers for preclinical sign onset? J Med Speech-Lang Patho 19(2):49\u201363","journal-title":"J Med Speech-Lang Patho"},{"issue":"4","key":"13310_CR17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1044\/jshd.5204.367","volume":"52","author":"RD Kent","year":"1987","unstructured":"Kent RD, Kent JF, Rosenbek JC (1987) Maximum performance tests of speech production. J Speech Hear Disord 52(4):367\u2013387","journal-title":"J Speech Hear Disord"},{"issue":"5","key":"13310_CR18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/jnnp.58.5.598","volume":"58","author":"KW Lange","year":"1995","unstructured":"Lange KW et al (1995) Comparison of executive and visuospatial memory function in Huntington\u2019s disease and dementia of Alzheimer type matched for degree of dementia. J Neurol Neurosurg Psychiatry 58(5):598\u2013606","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13310_CR19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1212\/WNL.0000000000002550","volume":"86","author":"S Skodda","year":"2016","unstructured":"Skodda S et al (2016) Two different phenomena in basic motor speech performance in premanifest Huntington disease. Neurology 86:1329\u20131335","journal-title":"Neurology"},{"issue":"2","key":"13310_CR20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0093-934X(87)90124-6","volume":"32","author":"CL Ludlow","year":"1987","unstructured":"Ludlow CL, Connor NP, Bassich CJ (1987) Speech timing in Parkinson\u2019s and Huntington\u2019s disease. Brain Lang 32(2):195\u2013214","journal-title":"Brain Lang"},{"key":"13310_CR21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00702-013-1115-9","volume":"121","author":"S Skodda","year":"2014","unstructured":"Skodda S et al (2014) Impaired motor speech performance in Huntington\u2019s disease. J Neural Transm 121:399\u2013407","journal-title":"J Neural Transm"},{"issue":"3","key":"13310_CR22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3233\/JHD-240021","volume":"13","author":"C Saft","year":"2024","unstructured":"Saft C et al (2024) Speech biomarkers in Huntington\u2019s disease: a longitudinal follow-up study in premanifest mutation carriers. J Huntingtons Dis 13(3):369\u2013373","journal-title":"J Huntingtons Dis"},{"issue":"5","key":"13310_CR23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Ghosh R, Leavitt BR (2019) Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 101(5):801\u2013819","journal-title":"Neuron"},{"key":"13310_CR24","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"AC Bachoud-Levi","year":"2019","unstructured":"Bachoud-Levi AC et al (2019) International guidelines for the treatment of Huntington\u2019s disease. Front Neurol 10:710","journal-title":"Front Neurol"},{"issue":"6","key":"13310_CR25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/jnnp-2019-322038","volume":"91","author":"KL Harris","year":"2020","unstructured":"Harris KL et al (2020) Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington\u2019s disease (Enroll-HD). J Neurol Neurosurg Psychiatry 91(6):622\u2013630","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"13310_CR26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/mds.870110406","volume":"11","author":"JP van Vugt","year":"1996","unstructured":"van Vugt JP, van Hilten BJ, Roos RA (1996) Hypokinesia in Huntington\u2019s disease. Mov Disord 11(4):384\u2013388","journal-title":"Mov Disord"},{"issue":"2","key":"13310_CR27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1388-2457(02)00371-1","volume":"114","author":"JP van Vugt","year":"2003","unstructured":"van Vugt JP et al (2003) Impaired antagonist inhibition may contribute to akinesia and bradykinesia in Huntington\u2019s disease. Clin Neurophysiol 114(2):295\u2013305","journal-title":"Clin Neurophysiol"},{"key":"13310_CR28","doi-asserted-by":"publisher","unstructured":"Faheem AD, Brightwell DR, Burton GC, Struss A (1982) Respiratory dyskinesia and dysarthria from prolonged neuroleptic use: tardive dyskinesia? American Journal of Psychiatry 139(4) 517-518 https:\/\/doi.org\/10.1176\/ajp.139.4.517","DOI":"10.1176\/ajp.139.4.517"},{"key":"13310_CR29","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00702-014-1229-8","volume":"121","author":"J Rusz","year":"2014","unstructured":"Rusz J et al (2014) Characteristics and occurrence of speech impairment in Huntington\u2019s disease: possible influence of antipsychotic medication. J Neural Transm 121:1529\u20131539","journal-title":"J Neural Transm"},{"issue":"7","key":"13310_CR30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ, Schobel S, Gantman EC et al (2022) A biological classification of Huntington\u2019s disease: the Integrated staging system. Lancet Neurol. 21(7):632\u201344","journal-title":"Lancet Neurol."},{"issue":"1","key":"13310_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.29.1.1","volume":"29","author":"I Shoulson","year":"1979","unstructured":"Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29(1):1\u20133","journal-title":"Neurology"},{"issue":"2","key":"13310_CR32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/JHD-210475","volume":"11","author":"JH Warner","year":"2022","unstructured":"Warner JH et al (2022) Standardizing the CAP score in Huntington\u2019s disease by predicting age-at-onset. J Huntingtons Dis 11(2):153\u2013171","journal-title":"J Huntingtons Dis"},{"issue":"4","key":"13310_CR33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mds.28465","volume":"36","author":"J Rusz","year":"2021","unstructured":"Rusz J et al (2021) Guidelines for speech recording and acoustic analyses in dysarthrias of movement disorders. Mov Disord 36(4):803\u2013814","journal-title":"Mov Disord"},{"key":"13310_CR34","doi-asserted-by":"publisher","unstructured":"Lena, Hartelius Malin, Lillvik (2003) Lip and Tongue Function Differently Affected in Individuals with Multiple Sclerosis Folia Phoniatrica et Logopaedica 55(1) 1-9 https:\/\/doi.org\/10.1159\/000068057","DOI":"10.1159\/000068057"},{"issue":"10","key":"13310_CR35","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1044\/2020_JSLHR-20-00109","volume":"63","author":"M Novotny","year":"2020","unstructured":"Novotny M et al (2020) Comparison of automated acoustic methods for oral diadochokinesis assessment in amyotrophic lateral sclerosis. J Speech Lang Hear Res 63(10):3453\u20133460","journal-title":"J Speech Lang Hear Res"},{"issue":"1\u20133","key":"13310_CR36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.schres.2013.06.030","volume":"149","author":"MX Patel","year":"2013","unstructured":"Patel MX et al (2013) How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res 149(1\u20133):141\u2013148","journal-title":"Schizophr Res"},{"key":"13310_CR37","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S et al (2016) Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 42:S90-94","journal-title":"Schizophr Bull"},{"issue":"3","key":"13310_CR38","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.neuroimage.2009.10.066","volume":"49","author":"HJ Huppertz","year":"2010","unstructured":"Huppertz HJ et al (2010) Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures. Neuroimage 49(3):2216\u20132224","journal-title":"Neuroimage"},{"issue":"10","key":"13310_CR39","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/mds.26715","volume":"31","author":"HJ Huppertz","year":"2016","unstructured":"Huppertz HJ et al (2016) Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. Mov Disord 31(10):1506\u20131517","journal-title":"Mov Disord"},{"issue":"3","key":"13310_CR40","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS et al (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31(3):968\u2013980","journal-title":"Neuroimage"},{"key":"13310_CR41","volume-title":"Statistical power analysis for the behavioral sciences 2","author":"J Cohen","year":"1998","unstructured":"Cohen J (1998) Statistical power analysis for the behavioral sciences 2. Lawrence Erlbaum Associates, Hillsdale, NJ"},{"issue":"1","key":"13310_CR42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ (1950) Index for rating diagnostic tests. Cancer 3(1):32\u201335","journal-title":"Cancer"},{"key":"13310_CR43","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2019","unstructured":"R Core Team (2019) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"key":"13310_CR44","unstructured":"Team, J., JASP (Version 0.16.1)[Computer software]. 2022."},{"issue":"10","key":"13310_CR45","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1007\/s00415-023-11823-x","volume":"270","author":"A Muhlback","year":"2023","unstructured":"Muhlback A et al (2023) Establishing normative data for the evaluation of cognitive performance in Huntington\u2019s disease considering the impact of gender, age, language, and education. J Neurol 270(10):4903\u20134913","journal-title":"J Neurol"},{"issue":"24","key":"13310_CR46","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","volume":"89","author":"SA Schobel","year":"2017","unstructured":"Schobel SA et al (2017) Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology 89(24):2495\u20132502","journal-title":"Neurology"},{"key":"13310_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropsychologia.2009.09.002","author":"JC Thompson","year":"2010","unstructured":"Thompson JC et al (2010) Automaticity and attention in Huntington\u2019s disease: when two hands are not better than one. Neuropsychologia. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2009.09.002","journal-title":"Neuropsychologia"},{"issue":"2","key":"13310_CR48","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.neuroimage.2006.04.173","volume":"32","author":"JW Bohland","year":"2006","unstructured":"Bohland JW, Guenther FH (2006) An fMRI investigation of syllable sequence production. Neuroimage 32(2):821\u2013841","journal-title":"Neuroimage"},{"issue":"1","key":"13310_CR49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1006\/nimg.2000.0672","volume":"13","author":"D Wildgruber","year":"2001","unstructured":"Wildgruber D, Ackermann H, Grodd W (2001) Differential contributions of motor cortex, basal ganglia, and cerebellum to speech motor control: effects of syllable repetition rate evaluated by fMRI. Neuroimage 13(1):101\u2013109","journal-title":"Neuroimage"},{"issue":"5180","key":"13310_CR50","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1126\/science.8091209","volume":"265","author":"AM Graybiel","year":"1994","unstructured":"Graybiel AM et al (1994) The basal ganglia and adaptive motor control. Science 265(5180):1826\u20131831","journal-title":"Science"},{"key":"13310_CR51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neuroimage.2013.05.064","volume":"82","author":"GP Argyropoulos","year":"2013","unstructured":"Argyropoulos GP, Tremblay P, Small SL (2013) The neostriatum and response selection in overt sentence production: an fMRI study. Neuroimage 82:53\u201360","journal-title":"Neuroimage"},{"key":"13310_CR52","first-page":"3","volume-title":"Clinical management of sensorimotor speech disorders","author":"A Van der Merwe","year":"2009","unstructured":"Van der Merwe A (2009) A theoretical framework for the characterization of pathological speech sensorimotor control. In: McNeil MR (ed) Clinical management of sensorimotor speech disorders. Thieme, New York, NY, pp 3\u201318"},{"issue":"3","key":"13310_CR53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0093-934X(92)90108-Q","volume":"43","author":"J Volkmann","year":"1992","unstructured":"Volkmann J et al (1992) Impairment of temporal organization of speech in basal ganglia diseases. Brain Lang 43(3):386\u2013399","journal-title":"Brain Lang"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13310-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13310-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13310-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:04:16Z","timestamp":1761699856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13310-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["13310"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13310-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article. A.M., K.S.L., G.B.L: Their institutions have received compensation for clinical trial services from the following companies: Hoffmann-La Roche, Novartis, Prilenia, Wave, SOM Biotech and from the CHDI Foundation as well as non-financial support (travel and accommodation reimbursement) from European Huntington\u00b4s Disease Network. W.H., L.S.: The authors received travel and accommodation reimbursement from European Huntington\u00b4s Disease Network. T.K., T.T., J. R., H.J.H, D.R.: The authors have no relevant financial or non-financial interests to disclose. J.L.: reports travel honoraria and speaker\u2019s fees from the CHDI Foundation, the Movement Disorders Society as the German Society for Cerebrospinal Fluid Diagnostic and Clinical Neurochemistry (DGLN), Alexion, Biogen, Sanofi, Teva, Merck, Novartis, Janssen, Fujirebio, Roche, and Neuraxpharm. His institution received financial compensation for clinical trials with JL as principal investigator from CHDI and SOM Biotech. He is member of the executive board of the DGLN. He received research funding from the German Federal Ministry of Education and Research (BMBF, CONNECT-GENERATE, 01GM1908B und\u00a001GM2208B) and\u00a0the Boehringer Ingelheim University Biocenter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Ethics Committee of the Ulm University, Germany (approval number: 381\/18) and was conducted in accordance with the ethical standards laid down in the Declaration of Helsinki of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All individual participants included in the study provided written informed consent for their participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"697"}}